New obesity drug tested in 348 people: which injection works best?

NCT ID NCT07226778

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 trial tested how the experimental drug maridebart cafraglutide (AMG 133) is absorbed when given as two different injections. 348 adults with overweight or obesity received a single dose. The main goal was to measure drug levels in the blood, not weight loss. Results will guide future studies on this potential obesity treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: maridebart cafraglutide (AMG 133)
What this could lead to: If successful, this could help determine the best way to give maridebart cafraglutide for weight management, potentially leading to a more effective obesity treatment.
What could go wrong: This is an early Phase 1 study focused on drug absorption, not on weight loss or safety. It may not lead to a proven treatment, and side effects or lack of efficacy could emerge in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

Anaheim Clinical Trials

Anaheim, California, 92801-2658, United States
Fortrea Clinical Research Unit - Dallas

Dallas, Texas, 75247-4989, United States
Fortrea Clinical Research Unit - Daytona Beach

Daytona Beach, Florida, 32117-5116, United States
Fortrea Clinical Research Unit Inc. - Madison

Madison, Wisconsin, 53704-2526, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.